Status:
UNKNOWN
Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
Lead Sponsor:
University Hospital, Brest
Conditions:
Myelodysplastic Syndromes
Myelodysplastic Syndrome With Isolated Del(5Q)
Eligibility:
All Genders
18+ years
Brief Summary
Myelodysplastic syndromes (MDS) are malignant hematopathies of the elderly characterized by persistent cytopenias and the presence of deregulated clonal hematopoiesis. The risk of progression to acute...
Eligibility Criteria
Inclusion
- Patients diagnosed with del5q MDS isolated or not
- The clinical and biological data are known at the time of diagnosis.
- The clinical and biological data are known 1 year after the diagnosis
- Consent for the collection of samples for research purposes
- Non-opposition obtained
Exclusion
- Patients under judicial protection (guardianship, ...)
- Refusal to participate
Key Trial Info
Start Date :
September 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04701229
Start Date
September 30 2020
End Date
September 30 2023
Last Update
January 8 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609
2
Groupe Français de cytogénétique Hématologique
Paris, France, 75000
3
Groupe Français des Myélodysplasies
Paris, France, 75000